![EpicShare | Share & Learn | Reducing the Cost of Cancer Care with Automated Dose Rounding and Biosimilars EpicShare | Share & Learn | Reducing the Cost of Cancer Care with Automated Dose Rounding and Biosimilars](https://epicshare.blob.core.windows.net/cms-uploads/media/UCSF-Mayo-Pharmacy-Savings-667x400.png)
EpicShare | Share & Learn | Reducing the Cost of Cancer Care with Automated Dose Rounding and Biosimilars
![Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/f9925654-2075-4af3-810f-b1d854511658/gr1_lrg.jpg)
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma | Haematologica
![Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01789-0/MediaObjects/41591_2022_1789_Fig1_HTML.png)
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
![Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804917307359-gr1.jpg)
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity - ScienceDirect
![783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ 783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ](https://www.eviq.org.au/getmedia/697d4ac9-e60a-4f9c-8492-1097b4f25eb0/Alliance-CALGB-50303-Bartlett-Fig-2.png.aspx)